Back to Blog
Analysis16 min read

Neuren (NEU) Up 17.5%: Culper's Daybue 'Flop' Is Now a US$500m Drug

Culper Research called Daybue a 'total flop' in 2024 and forecast US$316m in sales. Daybue has now sold US$366m in nine months of 2026 alone, and Neuren closed up 17.49% at $23.24 on the Q3 update. The full scorecard, the announcement line by line, and where shorts sat going in.

ASX Short Data5 November 2026
NEUNeurenhealthcareshort sellingDaybueRett syndromeAcadiaearningsCulper Research

In February 2024, US short seller Culper Research published a report calling Daybue, the Rett syndrome drug that Neuren Pharmaceuticals (NEU) earns royalties on, a "total flop". Culper forecast US$316m in 2024 sales and said peak sales would be "a mere fraction" of the US$800m analysts expected. Neuren fell 14% on the day.

In January we argued that the thesis had been dismantled, and in August a record quarter backed that up. Today's numbers leave very little of it standing.

Neuren closed at $23.24 on Thursday 5 November, up $3.46 or 17.49% from Wednesday's $19.78. That's the stock's second-biggest one-day gain of the past year, behind only the 36% jump on 29 June when Daybue was recommended for EU approval. The trigger was the Q3 2026 update from partner Acadia Pharmaceuticals, which Neuren lodged at 9:57am AEDT, just before the open.


Culper's forecasts vs what happened

Start with the numbers Culper put in writing.

Culper (Feb 2024) Actual / current Gap
2024 Daybue sales US$316m US$348m +10%
2026 Daybue sales US$505-520m (Acadia guidance) +60% to +65% vs Culper's 2024 forecast
First 9 months of 2026 alone US$366m Already 16% above Culper's full-year 2024 figure
Q3 2026 sales, annualised US$560m +77%
Peak sales "a mere fraction" of US$800m US$700m targeted for 2028 88% of the number Culper dismissed
Patients Poor retention; drug a "total flop" 76% still on therapy at 6 months (2024); STIX now bringing in new and returning patients

To be precise about it, Culper's 2024 forecast missed by about 10%. That alone could pass as an ordinary forecasting error. The bigger mistake was the claim behind it: that patients would drop off and sales were close to their ceiling. Instead, sales have grown every year: US$348m in 2024, US$391m in 2025, and US$505-520m guided for 2026. Nine months into 2026, Daybue had already sold more than Culper forecast for the whole of 2024, and full-year 2026 is on track to beat that forecast by about US$190-200m.

Since its April 2023 launch, the drug Culper called a flop has sold about US$1.28 billion (US$177m in 2023, US$348m in 2024, US$391m in 2025 and US$366m so far in 2026). It's now approved in the US, the EU, Canada and Israel, with US patent protection running to March 2041. Neuren paid its first dividend in October, funded by the royalties.


How the day traded

Price
Previous close (4 Nov) $19.78
Open $20.99
Low $20.98
High $23.30
Close $23.24
Change +$3.46 (+17.49%)
Market cap at close ~$2.95bn

The stock opened 6.1% higher and kept climbing through the first hour, passing $23 around 11am. It dipped to $22.75 just before midday, then traded between roughly $22.75 and $23.05 for most of the afternoon before closing 6 cents below the day's high.

At about 126.8 million shares on issue, the move added roughly $440 million to Neuren's market value in one session.

The $23.24 close is the highest since 14 August, about 1.7% below the closing high of $23.64 on 11 August. That means the stock has made back almost all of the ground it lost after the August rally (more on that below).


What the announcement said

Daybue sales

Metric Q3 2026 vs Q3 2025 vs Q2 2026
Daybue net sales US$140m +39% +12%
Neuren royalty income US$16.4m +51% +27%

The quarter-by-quarter run this year:

Quarter Daybue net sales Neuren royalty Royalty as % of sales
Q1 2026 US$101m US$10.4m 10.3%
Q2 2026 US$125m US$12.9m 10.3%
Q3 2026 US$140m US$16.4m 11.7%

Year-on-year growth has gone from 20% in Q1 to 30% in Q2 and 39% in Q3. Quarter-on-quarter growth slowed from 24% in Q2 to 12% in Q3.

Why royalties grew faster than sales

Royalties rose 51% while sales rose 39%. That's how the contract is built, not a one-off. Neuren's North American royalty is tiered on calendar-year net sales: 10% on the first US$250m, then 12% from US$250m to US$500m, with higher rates above that. The count resets each January, so the effective rate rises as the year goes on.

Cumulative 2026 sales were US$226m at the end of June. Q3 took them past US$250m, so about US$24m of Q3 sales earned 10% and the remaining US$116m earned 12%. That works out to about US$16.3m, in line with the reported US$16.4m. The effective rate jumped in Q3 because most of the quarter's sales fell in the 12% band, and Q4 sales will earn 12% too.

There's one more term in the contract that matters here. Under the licence agreement, Neuren receives a US$50m milestone in the first calendar year that North American net sales alone exceed US$500m. Acadia's 2026 guidance of US$505-520m is a global figure that now includes Germany, and Neuren's income guidance doesn't include this milestone. So the company isn't counting on reaching it this year, but at the current growth rate it's not far off.

Guidance

Metric Previous (Aug) Now (Nov) Change at midpoint
Acadia FY26 Daybue net sales US$480-510m US$505-520m +3.5%
Neuren FY26 royalty income US$53-56m US$56-58m +4.6%
Neuren FY26 total trofinetide income US$53-56m US$91-93m +69%

The total income line is the headline number, but it needs reading carefully. Most of the jump from US$53-56m to US$91-93m is the US$35m European milestone, which was already known about (see below). The underlying royalty upgrade is about US$2.5m at the midpoint.

The guidance also implies a range for Q4. With US$366m of sales booked in the first nine months, the full-year range of US$505-520m leaves US$139-154m for Q4, between 1% lower and 10% higher than Q3. On the royalty side, US$39.7m has been earned so far, which leaves US$16.3-18.3m for Q4. Acadia has raised guidance at each of the last two quarterly updates, but taken at face value, this guidance has growth leveling off in the last quarter rather than speeding up.

STIX

More than 50% of US Daybue patients were on the DAYBUE STIX powder formulation by the end of Q3, up from 40% at the end of Q2. Acadia put Q3 growth down to existing patients switching to STIX, plus new patient starts and patients restarting treatment.

Germany: the milestone is now earned

DAYBU (the European brand name) launched in Germany in October, and patients are already on treatment. The first commercial sale triggered a US$35m milestone payment to Neuren.

This wasn't a surprise. The payment was set out in the licence agreement and flagged again when the European Commission granted marketing authorisation on 25 August. What's new is that the launch happened in October, in line with the "early Q4" timing given in August, so the milestone has been earned and is now in guidance.

The European terms set out in today's announcement:

European annual net sales Royalty rate
Up to US$150m 17%
US$150m to US$300m 20%
Above US$300m 23%
Calendar-year European sales reach One-off milestone
US$120m US$15m
US$240m US$30m
US$400m US$50m
US$600m US$75m

The territory covers the EU as it stood in July 2023, plus the UK, Iceland, Norway, Switzerland and Liechtenstein.

Be careful with the royalty rate. 17-23% is well above the roughly 12% Neuren currently earns in North America, but a higher rate on a smaller sales base can still mean less money. Three things will limit how much Europe brings in:

  • Price. European drug prices are set country by country through health technology assessment and reimbursement negotiations, and are usually well below US prices. In Germany the launch price only applies for an initial period. After that a price is negotiated based on the benefit assessment. Neither Acadia nor Neuren has disclosed a European price.
  • Label. The EU approval covers patients aged five and older, while the US label covers patients aged two and older.
  • Timing. Germany is the only market so far. Other countries will follow as their own pricing and reimbursement processes finish, which usually takes months to years per country.

The first sales milestone needs US$120m of European sales in a single year. It's reasonable to treat Europe as a slow build rather than a second US.

Japan: the readout, in one sentence

The Japanese Phase 3 trial of trofinetide was one of the open risks we listed in August, with results then expected between September and November. Neuren didn't put out a separate announcement about it. Today's release covers it in one line: the results were "consistent with the LAVENDER Phase 3 study and supportive of a planned regulatory filing."

No efficacy data was released. Acadia is still looking for a Japanese distribution partner, plans to file in 2027, and is targeting a possible 2028 launch, subject to approval. So the trial risk has passed, but the market has the conclusion without the data.


Everything else since August

Date Announcement Move on the day
25 Aug European Commission grants marketing authorisation +0.4%
26 Aug H1 results and first-ever dividend (15c, fully franked) -10.6%
29 Sep US patent protection extended to March 2041 +2.3%
2 Nov FDA orphan drug designation for NNZ-2591 in HIE +1.9%
5 Nov Q3 update (this post) +17.5%

Two of these stand out.

The 26 August fall. NEU dropped 10.6% on the day it reported H1 results and declared its first dividend. Royalty income was up 29% to US$23.3m, but profit after tax fell to A$4.9m from A$15.0m. R&D costs rose by A$12.5m to A$27.4m, and there was also a A$4.7m loss on forward contracts to sell Australian dollars. That was the start of a slide from the 11 August closing high of $23.64 to $18.65 on 26 October, a 21% fall. Today's close recovers almost all of it.

The patent extension. A newly allowed patent covering weight-banded dosing extended US protection for Daybue and STIX to March 2041, almost five years later than before. For a company that depends on one drug's royalties, five more years of exclusivity is worth more than any single quarter. At the time, the stock rose 2.3%.


Short interest going into the result

The latest ASIC short position data is for 30 October, four trading days before the announcement.

Date Short interest Shares short
5 June 2026 (all-time high) 6.51% 8.22m
26 June 2026 (pre-CHMP) 5.94% 7.52m
31 July 2026 (pre-Q2) 5.41% 6.86m
28 August 2026 3.96% 5.02m
4 September 2026 3.03% 3.84m
9 October 2026 (low) 2.86% 3.62m
30 October 2026 (latest) 3.12% 3.95m

Short sellers have cut their position by 52% since the June peak. Most of the covering happened in two stretches: straight after the EU recommendation in late June (5.94% to 4.96% within a week), and from August into early September, when the position fell from 5.41% to 3.03%, or about 3 million shares.

After that, short interest stayed between about 2.85% and 3.1% for two months. In the last two weeks of October it rose from 2.87% on 19 October to 3.12% on 30 October, so some funds were adding to short positions ahead of the result. The same thing happened ahead of the Q2 update in July, when short interest rose from 4.88% to 5.41% in the fortnight before.

What it cost

Metric Value
Shares short (30 Oct) 3.95m
Short liability at 4 Nov close ($19.78) ~$78.2m
Short liability at 5 Nov close ($23.24) ~$91.9m
Paper loss on today's move (if positions unchanged) ~$13.7m
Days to cover (1-month average volume of 352k shares) ~11 days

At 11 days to cover, the remaining shorts can't close out quickly without moving the price. Whether covering added to today's move won't be known until ASIC publishes position data for 5 November next week.

Daily short sales

Gross daily short sales (new short selling each day, not the net position) were mostly between 12,000 and 100,000 shares through October. Two days stood out:

Date Short sales Total volume Short % of volume
27 Oct 145,416 445,914 32.6%
2 Nov 210,635 622,261 33.9%
3 Nov 51,890 378,646 13.7%
4 Nov 46,404 469,869 9.9%

On 2 November, the day of the HIE orphan drug announcement and three trading days before the Q3 update, a third of all volume was short selling. That's the largest daily short sale volume of the past month. Measured from that day's $20.75 close, any of those positions still open would be about 12% underwater at today's close. Short sale figures for 5 November will be published tomorrow.


Where this leaves the bear case

Culper's case was about the drug itself: that patients wouldn't stay on it and sales had little room left to grow. Every year of sales since has gone against it. What's left of the bear case is the ordinary risk that comes with any single-product royalty company. In August we listed four of those risks. Here's where each stands:

Risk (August 2026) Status (November 2026)
European Commission decision and launch timing Approved 25 Aug, launched in Germany in October, US$35m milestone earned
Japan Phase 3 readout "Consistent with LAVENDER", filing planned for 2027 (no data released)
Single-drug concentration Unchanged. Royalty income is still almost entirely from trofinetide
Dependence on Acadia Unchanged, and now also depends on Acadia finding a partner in Japan

Two of the four have been resolved in Neuren's favour. The other two are structural and won't change with any quarterly result. NNZ-2591 is the only route to diversifying, and its Phelan-McDermid Phase 3 (Koala) is still running.

Some fair points of caution remain:

  • Q4 guidance points to a slowdown. Taken literally, US$139-154m in Q4 is roughly flat on Q3.
  • Europe will be slow to build. The royalty rates are high, but European pricing, the narrower age range on the label and country-by-country reimbursement all limit the dollar amount (see above).
  • The August pattern. The last time NEU jumped on a quarterly result, it peaked six days later and then fell 21% over the next 11 weeks. That jump was 16.3%, similar in size to today's.
  • Japan details. "Supportive" covers a wide range of outcomes, and the size of the effect won't be known until Acadia publishes the data.

Summary

Culper said Daybue was a flop with peak sales well short of US$800m. Nearly three years later, it's guided to more than US$500m in sales this year, grew 39% year on year in the latest quarter, has launched in Europe and is protected by US patents to 2041. Culper wasn't just a little off on the numbers. It got the direction wrong.

Today's result was a strong quarter, but the 17.5% rise was a response to the whole picture rather than to one surprise. Sales were up 39%, Germany launched on schedule and the US$35m milestone has been earned. The Japan trial came back supportive, and the patent extension six weeks ago added almost five years of US protection. Over the two months before the result, the stock had drifted to between $19 and $20 while all of this was happening.

Short sellers have halved their position since June, though some added again in late October. About 3.95 million shares were still short going into today, worth around $92 million at the close and roughly 11 days of normal volume to buy back. ASIC's data next week will show whether they've stayed in.


Disclaimer: This blog post is for informational and educational purposes only and is not financial advice. The information provided is based on data available as of 5 November 2026. Short position data is as at 30 October 2026, the most recent ASIC report. Neuren Pharmaceuticals is a biotech stock with inherent risks, including regulatory uncertainty, single-product concentration and dependence on a commercial partner. You should do your own research and consult a qualified financial professional before making any investment decisions. ASXShort.app does not guarantee the accuracy or completeness of the data presented, nor does it guarantee future stock performance.

Sources:

Share this article: